>>Do you expect they will release something that will spell out even if they have to do a new clinical study or if these are questions about "non-clinical" data?<<
They probably won’t say anything more to investors on this subject until April, as indicated by the PR and reiterated on today’s webcast. However, if the company were to reach a determination that additional clinical trials will be needed, they would presumably deem this a material item mandating shareholder notification.
In other words, for the time being, no news is probably not a bad thing.
>>The last time, did anyone every find out what sort of questions they were asking?<<
On the previous iteration, GTCB informed investors that the EMEA’s questions did not pertain to ATryn’s efficacy or to concerns about transgenics per se. Beyond these exclusions, however, no details were provided.
It’s tough to make investing decisions based on such sketchy disclosures, but that’s the way the game is played.
Market Data 
Markets 
AI
